Research Article

Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom

Table 9

Costs of adverse events.

AEProbability that AE is seriousCost per AE, £Weighted average cost per AE, £
PazopanibPlaceboNonseriousSeriousPazopanibPlacebo

General
 Alopecia10000000
 Asthenia/fatigue 1517122122122122
 Hypertension 001222,234122122
 Myalgia/muscle pain400122122122122
 Neurotoxicity/peripheral sensory neuropathy1001001221,3201,3201,320
 Edema001221,602122122
Liver toxicity
 ALT elevation10001222,6642,664122
 AST elevation1001001222,6642,6642,664
Cardiovascular
 Cardiac toxicity10001223,8433,843122
 Left ventricular dysfunction 10001223,8433,843122
Pulmonary
 Dyspnea750122878689122
 Pleural effusion001221,974122122
 Pneumothorax100251221,9741,974585
 Pulmonary toxicity10001221,7131,713122
Gastrointestinal
 Decreased appetite/anorexia600122122122122
 Diarrhea 001221,171122122
 Nausea/vomiting 701221,171195122
 Weight decreased 90122122122122
Hematologic abnormalities
 Febrile neutropenia100671224,4174,4172,999
 Anemia/hemoglobin001221,482122122
 Leucopenia001224,417122122
 Neutropenia/neutrophils1001001224,4174,4174,417
 Thrombocytopenia/low platelets50501222,0511,0861,086

AE: adverse event; ALT: alanine aminotransferase; AST: aspartate aminotransferase.